Medtech Talk

Episode: 167 - M&A, IPO or SPAC: CEOs Share Exit Strategies and Lessons Learned Along the Way

04.19.2022 - By HealthegyPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Geoff Pardo and three successful medtech CEOs who exited their companies through a different pathway— M&A;, IPO, and SPAC—discuss the pros and cons of each. While market volatility is a given, Bruce Shook, Former President & CEO, Intact Vascular and Vesper Medical; Clint Carnell, Co-Founder & Chairman, OrangeTwist; Former CEO, BeautyHealth; and Leslie Trigg, CEO, Outset Medical agreed that successful CEOs keep their focus on delivering returns for their investors—whether private or public. If your company is solving a really important problem and is creating value for patients, you’ll ultimately succeed, Shook said. From there, Trigg pointed out, exit vehicles are simply different modes of transportation to the same place. 

GUESTS:

Bruce Shook, Former President & CEO, Intact Vascular and Vesper Medical 

Clint Carnell, Co-Founder & Chairman, OrangeTwist; Former CEO, BeautyHealth 

Leslie Trigg, CEO, Outset Medical, Inc.  HOST:  

Geoff Pardo, General Partner, Gilde Healthcare; Host, Medtech Talk podcast   LINKS:

Cambridge Healthtech Institute

Medtech Talk

Gilde Healthcare

OrangeTwist

Outset Medical 

More episodes from Medtech Talk